PMID- 36117326
OWN - NLM
STAT- MEDLINE
DCOM- 20230125
LR  - 20230125
IS  - 1472-8206 (Electronic)
IS  - 0767-3981 (Linking)
VI  - 37
IP  - 1
DP  - 2023 Feb
TI  - Activation of the Mas receptors by AVE0991 and MrgD receptor using alamandine to 
      limit the deleterious effects of Ang II-induced hypertension.
PG  - 60-74
LID - 10.1111/fcp.12829 [doi]
AB  - The MrgD receptor agonist, alamandine (ALA) and Mas receptor agonist, AVE0991 
      have recently been identified as protective components of the renin-angiotensin 
      system. We evaluated the effects of ALA and AVE0991 on cardiovascular function 
      and remodeling in angiotensin (Ang) II-induced hypertension in rats. Sprague 
      Dawley rats were subject to 4-week subcutaneous infusions of Ang II 
      (80 ng/kg/min) or saline after which they were treated with ALA (50 mug/kg), 
      AVE0991 (576 mug/kg), or ALA+AVE0991 during the last 2 weeks. Systolic blood 
      pressure (SBP) and heart rate (HR) values were recorded with tail-cuff 
      plethysmography at 1, 15, and 29 days post-treatment. After euthanization, the 
      heart and thoracic aorta were removed for further analysis and vascular 
      responses. SBP significantly increased in the Ang II group when compared to the 
      control group. Furthermore, Ang II also caused an increase in cardiac and aortic 
      cyclophilin-A (CYP-A), monocyte chemoattractant protein-1 (MCP-1), and 
      cardiomyocyte degeneration but produced a decrease in vascular relaxation. HR, 
      matrix metalloproteinase-2 and -9, NADPH oxidase-4, and lysyl oxidase levels were 
      comparable among groups. ALA, AVE0991, and the drug combination produced 
      antihypertensive effects and alleviated vascular responses. The inflammatory and 
      oxidative stress related to cardiac MCP-1 and CYP-A levels decreased in the Ang 
      II+ALA+AVE0991 group. Vascular but not cardiac angiotensin-converting enzyme-2 
      levels decreased with Ang II administration but were similar to the Ang 
      II+ALA+AVE0991 group. Our experimental data showed the combination of ALA and 
      AVE0991 was found beneficial in Ang II-induced hypertension in rats by reducing 
      SBP, oxidative stress, inflammation, and improving vascular responses.
CI  - (c) 2022 Societe Francaise de Pharmacologie et de Therapeutique. Published by John 
      Wiley & Sons Ltd.
FAU - Tanriverdi, Lokman Hekim
AU  - Tanriverdi LH
AUID- ORCID: 0000-0003-4263-5234
AD  - Department of Medical Pharmacology, Faculty of Medicine, Inonu University, 
      Malatya, Turkiye.
FAU - Ozhan, Onural
AU  - Ozhan O
AUID- ORCID: 0000-0001-9018-7849
AD  - Department of Medical Pharmacology, Faculty of Medicine, Inonu University, 
      Malatya, Turkiye.
FAU - Ulu, Ahmet
AU  - Ulu A
AD  - Biochemistry and Biomaterials Research Laboratory, Department of Chemistry, 
      Faculty of Science, Inonu University, Malatya, Turkiye.
FAU - Yildiz, Azibe
AU  - Yildiz A
AD  - Department of Histology and Medical Embryology, Faculty of Medicine, Inonu 
      University, Malatya, Turkiye.
FAU - Ates, Burhan
AU  - Ates B
AD  - Biochemistry and Biomaterials Research Laboratory, Department of Chemistry, 
      Faculty of Science, Inonu University, Malatya, Turkiye.
FAU - Vardi, Nigar
AU  - Vardi N
AD  - Department of Histology and Medical Embryology, Faculty of Medicine, Inonu 
      University, Malatya, Turkiye.
FAU - Acet, Haci Ahmet
AU  - Acet HA
AD  - Department of Medical Pharmacology, Faculty of Medicine, Inonu University, 
      Malatya, Turkiye.
FAU - Parlakpinar, Hakan
AU  - Parlakpinar H
AUID- ORCID: 0000-0001-9497-3468
AD  - Department of Medical Pharmacology, Faculty of Medicine, Inonu University, 
      Malatya, Turkiye.
LA  - eng
GR  - TCD-2020-2172/Inonu University Scientific Research Projects Unit/
PT  - Journal Article
DEP - 20220926
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 0 (alamandine)
RN  - 11128-99-7 (Angiotensin II)
RN  - 0 (AVE 0991)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (Mrgprd protein, rat)
SB  - IM
MH  - Animals
MH  - Rats
MH  - *Angiotensin II
MH  - *Hypertension/chemically induced/drug therapy
MH  - Matrix Metalloproteinase 2
MH  - Rats, Sprague-Dawley
MH  - Receptors, G-Protein-Coupled/agonists
OTO - NOTNLM
OT  - AVE0991
OT  - NADPH oxidase
OT  - alamandine
OT  - angiotensin II
OT  - cyclophilin A
OT  - hypertension
EDAT- 2022/09/20 06:00
MHDA- 2023/01/25 06:00
CRDT- 2022/09/19 01:53
PHST- 2022/08/16 00:00 [revised]
PHST- 2022/07/04 00:00 [received]
PHST- 2022/09/06 00:00 [accepted]
PHST- 2022/09/20 06:00 [pubmed]
PHST- 2023/01/25 06:00 [medline]
PHST- 2022/09/19 01:53 [entrez]
AID - 10.1111/fcp.12829 [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2023 Feb;37(1):60-74. doi: 10.1111/fcp.12829. Epub 2022 
      Sep 26.